Francesca Del Gaudio

Francesca Del Gaudio

Auto-generated profile, based on publicly available information

Francesca Del Gaudio

Department of Medicine (Huddinge), Karolinska Institutet, Huddinge, Sweden

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2018 in Nature
Verified
Journal Article
Closed access
PDF file
MVMichael Vanlandewijck
Michael Vanlandewijck
LHLiqun He
Liqun He
MMMaarja Andaloussi Mäe
Maarja Andaloussi Mäe
JAJohanna Andrae
Johanna Andrae
KAKoji Ando
Koji Ando
CBChrister Betsholtz
Christer Betsholtz

21 August 2018 in Scientific Data
Verified
Journal Article
Open access
PDF file
LHLiqun He
Liqun He
MVMichael Vanlandewijck
Michael Vanlandewijck
MMMaarja Andaloussi Mäe
Maarja Andaloussi Mäe
JAJohanna Andrae
Johanna Andrae
KAKoji Ando
Koji Ando
CBChrister Betsholtz
Christer Betsholtz
Vascular diseases are major causes of death, yet our understanding of the cellular constituents of blood vessels, including how differences in their gene expression profiles create diversity in vascular structure and function, is limited. In this paper, we describe a single-cell RNA sequencing (scRNA-seq) dataset that defines vascular and vessel-associated cell types and subtypes in mouse brain and lung. The dataset contains 3,436 single cell transcriptomes from mouse brain, which formed 15 distinct clusters corresponding to cell (sub)types, and another 1,504 single cell transcriptomes from mouse lung, which formed 17 cell clusters. In order to allow user-friendly access to our data, we constructed a searchable database (http://betsholtzlab.org/VascularSingleCells/database.html). Our dataset constitutes a comprehensive molecular atlas of vascular and vessel-associated cell types in the mouse brain and lung, and as such provides a strong foundation for future studies of vascular development and diseases.

27 April 2022 in Open Biology
Verified
Journal Article
Open access
FGFrancesca Del Gaudio
Francesca Del Gaudio
DLDongli Liu
Dongli Liu
ULUrban Lendahl
Urban Lendahl
Notch signalling is an evolutionarily highly conserved signalling mechanism governing differentiation and regulating homeostasis in many tissues. In this review, we discuss recent advances in our understanding of the roles that Notch signalling plays in the vasculature. We describe how Notch signalling regulates different steps during the genesis and remodelling of blood vessels (vasculogenesis and angiogenesis), including critical roles in assigning arterial and venous identities to the emerging blood vessels and regulation of their branching. We then proceed to discuss how experimental perturbation of Notch signalling in the vasculature later in development affects vascular homeostasis. In this review, we also describe how dysregulated Notch signalling, as a consequence of direct mutations of genes in the Notch pathway or aberrant Notch signalling output, contributes to various types of vascular disease, including CADASIL, Snedden syndrome and pulmonary arterial hypertension. Finally, we point out some of the current knowledge gaps and identify remaining challenges in understanding the role of Notch in the vasculature, which need to be addressed to pave the way for Notch-based therapies to cure or ameliorate vascular disease.

15 February 2016 in Oncogene
Verified
Journal Article
Open access
GFGiulia Franciosa
Giulia Franciosa
GDG Diluvio
G Diluvio
FGF Del Gaudio
F Del Gaudio
MGM V Giuli
M V Giuli
RPRocco Palermo
Rocco Palermo
SCSaula Checquolo
Saula Checquolo
Deregulated Notch signaling is associated with T-cell Acute Lymphoblastic Leukemia (T-ALL) development and progression. Increasing evidence reveals that Notch pathway has an important role in the invasion ability of tumor cells, including leukemia, although the underlying molecular mechanisms remain mostly unclear. Here, we show that Notch3 is a novel target protein of the prolyl-isomerase Pin1, which is able to regulate Notch3 protein processing and to stabilize the cleaved product, leading to the increased expression of the intracellular domain (N3IC), finally enhancing Notch3-dependent invasiveness properties. We demonstrate that the combined inhibition of Notch3 and Pin1 in the Notch3-overexpressing human leukemic TALL-1 cells reduces their high invasive potential, by decreasing the expression of the matrix metalloprotease MMP9. Consistently, Pin1 depletion in a mouse model of Notch3-induced T-ALL, by reducing N3IC expression and signaling, impairs the expansion/invasiveness of CD4+CD8+ DP cells in peripheral lymphoid and non-lymphoid organs. Notably, in in silico gene expression analysis of human T-ALL samples we observed a significant correlation between Pin1 and Notch3 expression levels, which may further suggest a key role of the newly identified Notch3-Pin1 axis in T-ALL aggressiveness and progression. Thus, combined suppression of Pin1 and Notch3 proteins may be exploited as an additional target therapy for T-ALL.

25 May 2018 in Oncogenesis
Verified
Journal Article
Open access
PDF file
GDGiulia Diluvio
Giulia Diluvio
FGFrancesca Del Gaudio
Francesca Del Gaudio
MGMaria Valeria Giuli
Maria Valeria Giuli
GFGiulia Franciosa
Giulia Franciosa
EGEugenia Giuliani
Eugenia Giuliani
SCSaula Checquolo
Saula Checquolo
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome. However, the importance of individual receptors in TNBC and their specific mechanism of action remain to be elucidated, even if recent findings suggested a specific role of activated-Notch3 in a subset of TNBCs. Epidermal growth factor receptor (EGFR) is overexpressed in TNBCs but the use of anti-EGFR agents (including tyrosine kinase inhibitors, TKIs) has not been approved for the treatment of these patients, as clinical trials have shown disappointing results. Resistance to EGFR blockers is commonly reported. Here we show that Notch3-specific inhibition increases TNBC sensitivity to the TKI-gefitinib in TNBC-resistant cells. Mechanistically, we demonstrate that Notch3 is able to regulate the activated EGFR membrane localization into lipid rafts microdomains, as Notch3 inhibition, such as rafts depletion, induces the EGFR internalization and its intracellular arrest, without involving receptor degradation. Interestingly, these events are associated with the EGFR tyrosine dephosphorylation at Y1173 residue (but not at Y1068) by the protein tyrosine phosphatase H1 (PTPH1), thus suggesting its possible involvement in the observed Notch3-dependent TNBC sensitivity response to gefitinib. Consistent with this notion, a nuclear localization defect of phospho-EGFR is observed after combined blockade of EGFR and Notch3, which results in a decreased TNBC cell survival. Notably, we observed a significant correlation between EGFR and NOTCH3 expression levels by in silico gene expression and immunohistochemical analysis of human TNBC primary samples. Our findings strongly suggest that combined therapies of TKI-gefitinib with Notch3-specific suppression may be exploited as a drug combination advantage in TNBC treatment.

16 December 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
DODaniel V Oliveira
Daniel V Oliveira
KCKirsten Coupland
Kirsten Coupland
WSWenchao Shao
Wenchao Shao
SJShaobo Jin
Shaobo Jin
FGFrancesca Del Gaudio
Francesca Del Gaudio
HKHelena Karlström
Helena Karlström
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic form of familial small vessel disease; no preventive or curative therapy is available. CADASIL is caused by mutations in the NOTCH3 gene, resulting in a mutated NOTCH3 receptor, with aggregation of the NOTCH3 extracellular domain (ECD) around vascular smooth muscle cells. In this study, we have developed a novel active immunization therapy specifically targeting CADASIL‐like aggregated NOTCH3 ECD. Immunizing CADASIL TgN3R182C 150 mice with aggregates composed of CADASIL‐R133C mutated and wild‐type EGF 1–5 repeats for a total of 4 months resulted in a marked reduction (38–48%) in NOTCH3 deposition around brain capillaries, increased microglia activation and lowered serum levels of NOTCH3 ECD. Active immunization did not impact body weight, general behavior, the number and integrity of vascular smooth muscle cells in the retina, neuronal survival, or inflammation or the renal system, suggesting that the therapy is tolerable. This is the first therapeutic study reporting a successful reduction of NOTCH3 accumulation in a CADASIL mouse model supporting further development towards clinical application for the benefit of CADASIL patients.